Clinical Trial Update: Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study update for RMC-6291 monotherapy in KRASG12C-mutant solid tumors, outlining dose-escalation and dose-expansion cohorts in subjects with advanced di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• RMC-6291

Snippet

Sponsor: Revolution Medicines, Inc. | Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Status: ACTIVE_NOT_RECRUITING